- Home
- MHN vs CATX Comparison
MHN vs CATX Comparison
Compare MHN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.40
Company Overview
Basic Information| Metric | MHN | CATX |
|---|---|---|
| Founded | 1997 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 162.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MHN | CATX |
|---|---|---|
| Price | $10.39 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 59.2K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.69 | $1.60 |
| 52 Week High | $10.81 | $5.39 |
Technical Indicators
Market Signals| Indicator | MHN | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 48.74 |
| Support Level | $10.23 | $2.07 |
| Resistance Level | $10.51 | $2.39 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 49.15 | 75.13 |
Price Performance
Historical Comparison MHN
CATX
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.